LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Long-term Debt
Borrowings due after more than one year.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $0, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Long-term debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 24.15M | — |
Long-term Debt vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 long-term debt of $0 is the 7th highest of the 10 companies compared; the peer median is $3.56M.
- Long-term debt amounts to 0.0% of total assets for LBRX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $71.74M | — | — | 0.1% | |
| Sep 2026 | $57.32M | — | — | 3.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $36.66M | -9.2% | — | 3.4% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $8.19M | — | -5.8% | 1.6% |
| Mar 2026 | $3.56M | -83.2% | -64.0% | 1.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $119K | — | — | 0.1% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Jun 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $3.56M | -46.2% | -34.9% | 0.1% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.